Heart Booster: a pericardial support device

Kung, R. T. V.; Rosenberg, Mark

doi:10.1016/s0003-4975(99)00524-x

Cited by 31 publications

(24 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Artrip and associates have proved in laboratory studies that such director cardiac compression system devices are limited to short‐term applications but demonstrate significant improvements in cardiac output when applied to the acutely failing heart (6,7).…”

Section: Discussionmentioning

confidence: 99%

An Artificial Myocardium Assist System: Electrohydraulic Ventricular Actuation Improves Myocardial Tissue Perfusion in Goats

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

An Artificial Myocardium Assist System: Electrohydraulic Ventricular Actuation Improves Myocardial Tissue Perfusion in Goats

et al. 2004

View full text Add to dashboard Cite

show abstract

“…In fact, blood clots are the leading cause ofdeath in patients on VADs (Shahinpoor, 2010). To address the shortcomings of blood contacting assist devices, a number of non-blood contacting devices are currently under development (Alazmani et al, 2012;Kung & Rosenberg, 1999;Moreno et al, 2011b;Oz et al, 2002) although none have received FDA approval yet.…”

Section: Medical Problemmentioning

confidence: 99%

“…The device was designed to operate with low volumes because the device was intended to be a fully implantable device. Unlike the previous devices, it was designed for long term support rather than acute interventions (Kung & Rosenberg, 1999).…”

Section: T~iercasementioning

confidence: 99%

“…The device was designed to be implanted minimally invasively (through a mini thoracotomy) and anchored to the pericardium attachment, but this attachment method is prone to creep in the long term. In an in vitro model, the device must be operated at about 100 kPa for physiological blood flow rates at a physiological afterload (6L/min at 115torr) (Kung & Rosenberg, 1999). The Heart Patch device can be delivered minimally invasively and is left in place for two weeks before initiating cardiac compression so that biointegration can occur to hold the patches in place.…”

Section: T~iercasementioning

confidence: 99%

See 1 more Smart Citation

Soft Pneumatic Artificial Muscles With Low Threshold Pressures for a Cardiac Compression Device

Obiajulu

Roche

Pigula

et al. 2013

Volume 6A: 37th Mechanisms and Robotics Conference

View full text Add to dashboard Cite

In this paper, I present the design, fabrication and characterization of fully soft pneumatic artificial muscles (PAMs) with low threshold pressures that are intended for direct cardiac compression (DCC). McKibben type PAMs typically have a threshold pressure of at least lOOkPa and require rigid end fittings which may damage soft tissue and cause local stress concentrations, and thus failure points in the actuator. The actuator design I present is a variant on the McKibben PAM with the following key differences: the nylon mesh is embedded in the elastomeric tube, and closure of the end of the tube is achieved without rigid ends. The actuators were tested to investigate the effects of mesh geometry and elastomer material on force output, contraction, and rise time. Lower initial braid angles and softer elastomer materials provided the best force, contraction, and rise times; Up to 50N of force, 24% contraction, and response times of 0.05s were achieved at 100kPa. The actuators exhibited low threshold pressures (<5kPa) and high rupture pressures (138kPa -720kPa) which suggest safe operation for the DCC application. These results demonstrate that the actuators can achieve forces, displacements, and rise times suitable to assist with cardiac function.

show abstract

“…Potential advantages of this approach include (i) large compressive volume displacement; (ii) can tune actuation volume to match MEC output; (iii) provides passive restraint when not active; and (iv) a pneumatic version of the target device has been tested in sheep and calf models with promising results (11,12). Potential difficulties include (i) higher MEC power requirements relative to other approaches ( c .…”

Section: Prospective Non‐blood‐contacting Solutionsmentioning

confidence: 99%

Potential Mechanisms for Muscle‐Powered Cardiac Support

Trumble

2011

Artificial Organs

View full text Add to dashboard Cite

Biomechanical actuation of an implanted ventricular assist device (VAD) is an attractive means of providing long-term circulatory support. Studies show that energy from electrically stimulated skeletal muscle can, in principle, be used to provide tether-free cardiac assistance without the need for percutaneous drivelines or bulky energy transmission hardware. A mechanical prosthesis designed to harness the contractile power of in situ skeletal muscle has been developed in this laboratory that collects energy from the latissimus dorsi muscle and transmits it in the form of hydraulic power. In order to use this technique to pump blood however, a practical means to deliver this energy to the bloodstream must be devised. Presented here are six prospective mechanisms designed to accomplish this task, five of which also eliminate blood contacting surfaces that often lead to thromboembolic complications in chronic VAD patients.

show abstract

Heart Booster: a pericardial support device

Cited by 31 publications

References 7 publications

An Artificial Myocardium Assist System: Electrohydraulic Ventricular Actuation Improves Myocardial Tissue Perfusion in Goats

An Artificial Myocardium Assist System: Electrohydraulic Ventricular Actuation Improves Myocardial Tissue Perfusion in Goats

Soft Pneumatic Artificial Muscles With Low Threshold Pressures for a Cardiac Compression Device

Potential Mechanisms for Muscle‐Powered Cardiac Support

Contact Info

Product

Resources

About